An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senzime secures a three-year GPO contract with a major US hospital system as the sole source supplier for the TetraGraph monitoring system. The agreement grants access to over 40 hospitals across 11 US states, serving 12.5 million patients annually. Senzime's CEO highlights the significance of being the exclusive supplier to one of the largest IDNs in the US market, emphasizing the validation of their technology and commitment to patient safety. The TetraGraph system aids anesthesiologists in accurately administering neuromuscular blocking drugs during surgery, ensuring patient safety and optimal recovery.
Senzime ottiene un contratto di GPO triennale con un importante sistema ospedaliero statunitense come unico fornitore del sistema di monitoraggio TetraGraph. L'accordo fornisce accesso a oltre 40 ospedali in 11 stati degli USA, servendo annualmente 12,5 milioni di pazienti. Il CEO di Senzime sottolinea l'importanza di essere il fornitore esclusivo di uno dei più grandi IDN sul mercato statunitense, evidenziando la validazione della loro tecnologia e l'impegno per la sicurezza dei pazienti. Il sistema TetraGraph assiste gli anestesisti nell'amministrazione precisa di farmaci bloccanti neuromuscolari durante gli interventi chirurgici, garantendo la sicurezza del paziente e un recupero ottimale.
Senzime asegura un contrato de GPO de tres años con un importante sistema hospitalario de EE. UU. como el único proveedor del sistema de monitoreo TetraGraph. El acuerdo permite acceso a más de 40 hospitales en 11 estados de EE. UU., atendiendo anualmente a 12.5 millones de pacientes. El CEO de Senzime destaca la importancia de ser el proveedor exclusivo de una de las redes de atención sanitaria integradas más grandes del mercado estadounidense, enfatizando la validación de su tecnología y el compromiso con la seguridad del paciente. El sistema TetraGraph ayuda a los anestesiólogos a administrar de manera precisa los medicamentos bloqueadores neuromusculares durante la cirugía, asegurando la seguridad del paciente y una recuperación óptima.
Senzime은 주요 미국 병원 시스템과의 3년간의 GPO 계약을 확보하여 TetraGraph 모니터링 시스템의 유일한 공급업체가 되었습니다. 이 계약은 미국 11개 주에 있는 40개 이상의 병원에 접근을 제공하며 매년 1,250만 명의 환자를 서비스합니다. Senzime의 CEO는 미국 시장에서 가장 큰 통합 의료 네트워크의 독점 공급업체가 되는 것의 중요성을 강조하면서, 그들의 기술의 검증과 환자 안전에 대한 헌신을 강조했습니다. TetraGraph 시스템은 마취과 의사가 수술 중 신경근 차단 약물을 정확하게 투여하는 데 도움을 주어 환자의 안전을 보장하고 최적의 회복을 도모합니다.
Senzime sécurise un contrat de GPO de trois ans avec un grand système hospitalier américain en tant que fournisseur unique pour le système de surveillance TetraGraph. L'accord offre l'accès à plus de 40 hôpitaux dans 11 états des États-Unis, desservant annuellement 12,5 millions de patients. Le PDG de Senzime souligne l'importance d'être le fournisseur exclusif de l'un des plus grands réseaux de prestataires de soins intégrés sur le marché américain, mettant en avant la validation de leur technologie et leur engagement envers la sécurité des patients. Le système TetraGraph aide les anesthésistes à administrer avec précision les médicaments de blocage neuromusculaire pendant la chirurgie, assurant la sécurité des patients et une récupération optimale.
Senzime sichert einen dreijährigen GPO-Vertrag mit einem großen US-Krankenhaussystem als alleiniger Lieferant für das TetraGraph-Überwachungssystem. Die Vereinbarung gewährt Zugang zu über 40 Krankenhäusern in 11 US-Bundesstaaten und betreut jährlich 12,5 Millionen Patienten. Der CEO von Senzime betont die Bedeutung, exklusiver Lieferant eines der größten integrierten Gesundheitsnetzwerke auf dem US-Markt zu sein, und hebt die Validierung ihrer Technologie sowie das Engagement für die Patientensicherheit hervor. Das TetraGraph-System unterstützt Anästhesisten bei der genauen Verabreichung von neuromuskulären Blockiermitteln während Operationen, um die Sicherheit der Patienten und eine optimale Erholung sicherzustellen.
Positive
None.
Negative
None.
UPPSALA, SWEDEN / ACCESSWIRE / April 26, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) has secured a three-year GPO contract with one of the largest hospital and managed care organizations in the US for the TetraGraph monitoring system. The sole source agreement includes TetraGraph as the only stand-alone EMG-based quantitative neuromuscular monitor available on contract, giving access to over 40 hospitals that serve over 12.5 million patients annually across 11 US states.
"Signing a GPO contract is certainly a key milestone for us as it validates the hospital market demand for our solutions. But being the sole source supplier to one the largest IDNs in the US market is really a landmark for Senzime as it validates our unique technology, our capabilities and our relentless strive for patient safety", comments Senzime's CEO Philip Siberg.
Every year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing; hence, accurate monitoring during surgery to secure each patient's individual dose is paramount for a safe and timely recovery.
Senzime's TetraGraph is a state-of-the-art quantitative train-of-four (TOF) neuromuscular monitoring system used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology helps anesthesiologists accurately select the right dose of neuromuscular blocking drugs and their antagonists allowing for patients to safely recover following surgery.
Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.
